Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Operations: 2016-2025

Historic Cash from Operations for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$23.2 million.

  • Tg Therapeutics' Cash from Operations fell 89.70% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 149.49%. This contributed to the annual value of -$40.5 million for FY2024, which is 28.98% down from last year.
  • Tg Therapeutics' Cash from Operations amounted to -$23.2 million in Q3 2025, which was down 411.36% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Operations peaked at $83.7 million during Q3 2023, and registered a low of -$86.9 million during Q4 2021.
  • Over the past 3 years, Tg Therapeutics' median Cash from Operations value was -$13.2 million (recorded in 2023), while the average stood at -$10.6 million.
  • In the last 5 years, Tg Therapeutics' Cash from Operations surged by 342.66% in 2023 and then plummeted by 249.88% in 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Operations (Quarterly) stood at -$86.9 million in 2021, then skyrocketed by 72.53% to -$23.9 million in 2022, then skyrocketed by 44.66% to -$13.2 million in 2023, then slumped by 94.10% to -$25.6 million in 2024, then plummeted by 89.70% to -$23.2 million in 2025.
  • Its Cash from Operations was -$23.2 million in Q3 2025, compared to $7.4 million in Q2 2025 and -$28.7 million in Q1 2025.